Email Post: CSIG-20. INHIBITION OF AKT/SURVIVIN AND AKT/ID3 PATHWAYS BY CELECOXIB, A SELECTIVE COX-2 INHIBITOR, MAY HAVE PROMISING THERAPEUTIC POTENTIAL IN LOW-GRADE GLIOMA